Securities Code: 300199 Securities Abbreviation: Hanmi Pharmaceutical Announcement No.: 2026-043
Shenzhen Hanmi Pharmaceutical Co., Ltd.
Announcement on Acceptance of Marketing Application for Semaglutide Injection (Weight Loss) in Cooperation with Sanshengmandi
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
I. Background of Cooperation with Sanshengmandi
In May 2024, Shenzhen Hanmi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Hanmi Pharmaceutical") signed the "Cooperation Agreement on Semaglutide Injection Products" with Zhejiang Sanshengmandi Pharmaceutical Co., Ltd. (hereinafter referred to as "Sanshengmandi"). According to the agreement, the two parties have reached a cooperation on the commercialization of Semaglutide Injection (weight loss indication) in mainland China.
In August 2025, the two parties signed the "Contract Manufacturing and Supply Agreement," "Drug Contract Manufacturing Quality Agreement," and "Supplementary Agreement to the Cooperation Agreement on Semaglutide Injection I" to clarify matters related to product approval and listing, production, and supply in advance.
This cooperation fully integrates the complementary advantages of both parties in the fields of "R&D and Production" and "Commercialization":
Hanmi Pharmaceutical (Technology Side): As the entrusted R&D and manufacturing party for the Marketing Authorization Holder (MAH), leveraging its accumulated solid-phase synthesis technology in the peptide drug field, large-scale production capacity, and drug registration experience, it is responsible for the process development, clinical research, production supply, and quality assurance of Semaglutide Injection, ensuring t